GT Biopharma (GTBP) Common Equity (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Common Equity of $7.6 million for Q1 2026, up 873.47% year-over-year from $778658.3 in Q1 2025, and up 30.98% quarter-over-quarter from $5.8 million in Q4 2025.
GT Biopharma (GTBP) Common Equity (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Common Equity for 17 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 873.47% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (up 873.47% YoY), while the FY2025 annual figure was $5.8 million, up 446.53% from the prior year.
- Common Equity climbed to $7.6 million in Q1 2026 per GTBP's latest filing, from $5.8 million in the prior quarter.
- Across five years, Common Equity topped out at $17.8 million in Q1 2022 and bottomed at -$25.9 million in Q2 2025.
- Historically, Common Equity has averaged $6.1 million across 5 years, with a median of $7.5 million in 2023.
- Annual changes were most pronounced in 2025 — Common Equity slumped 569.77% — and 2026, when it jumped 873.47%.
- GT Biopharma's Common Equity stood at $11.7 million in 2022, then slumped by 36.29% to $7.5 million in 2023, then plunged by 122.34% to -$1.7 million in 2024, then soared by 446.53% to $5.8 million in 2025, then soared by 30.98% to $7.6 million in 2026.
- Business Quant data shows GTBP's Common Equity at $7.6 million in Q1 2026, $5.8 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | 7.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.58 Mn |
| Dec 31, 2025 | 5.79 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | -25.88 Mn |
| Mar 31, 2025 | -980,000.00 |
| Dec 31, 2024 | -1.67 Mn |
| Sep 30, 2024 | 2.10 Mn |
| Jun 30, 2024 | 5.51 Mn |
| Mar 31, 2024 | 5.31 Mn |
| Dec 31, 2023 | 7.48 Mn |
| Sep 30, 2023 | 10.01 Mn |
| Jun 30, 2023 | 11.76 Mn |
| Mar 31, 2023 | 13.05 Mn |
| Dec 31, 2022 | 11.73 Mn |
| Sep 30, 2022 | 15.95 Mn |
| Jun 30, 2022 | 15.44 Mn |
| Mar 31, 2022 | 17.79 Mn |
| Dec 31, 2021 | 21.91 Mn |
| Sep 30, 2021 | 31.88 Mn |
| Jun 30, 2021 | 36.29 Mn |